Roche makes four pipeline changes on back of trial failures, but sees path ahead for three therapies
Roche is reworking its plans for a quartet of clinical programs spanning different therapeutic areas and stages of development, but it may not be the end of the road for most of the drugs affected.
The Swiss drugmaker revealed it was dropping its Phase I solid tumor trial for cibisatamab, as well as Phase II programs for ralmitaront in schizophrenia and vicasinabin in diabetic retinopathy, according to a pipeline document released as part of Thursday’s third-quarter earnings update.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.